Terumo Corporation Revises Earnings Forecast — Adjusted Operating Income Up 14.7%

Terumo Corporation Revises Earnings Forecast — Adjusted Operating Income Up 14.7%

Terumo Corporation (TSE:4543) raised its earnings guidance for the fiscal year ending March 2027, driven by a U.S. tariff refund and settlement proceeds received in the first quarter.

The medical device manufacturer left its full-year revenue forecast unchanged at JPY 1239.0bn but significantly increased profitability metrics. Operating profit rose to JPY 274.5bn from JPY 261.5bn, a JPY 13.0bn increase. More notably, adjusted operating income climbed JPY 33.0bn to JPY 257.5bn, reflecting a 14.7% upward revision. Net profit attributable to parent company shareholders jumped JPY 27.8bn to JPY 193.1bn, a 16.8% gain. Basic earnings per share were raised to JPY 130.91 from JPY 112.06.

Management attributed the revision to two non-operating items recognized in the first quarter: a refund related to U.S. tariffs and proceeds from a settlement agreement. These one-time gains significantly boosted bottom-line profitability without affecting core operational revenue.

The upward revision signals improved cash generation for the fiscal year, though investors should note the gains are largely non-recurring in nature. The unchanged revenue guidance suggests management maintains confidence in underlying business momentum, while the profit uplift provides near-term financial flexibility. Terumo’s adjusted operating income margin expanded materially, indicating operational efficiency gains alongside the favorable one-time items.

Source: Original filing (TDnet) | 日本語版

This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.